Cited by 265Gestational Diabetes Research and ManagementDiabetes Management and ResearchPregnancy and Medication Impact

Maternal Glycemic Control and Hypoglycemia in Type 1 Diabetic Pregnancy

Open access
Mathiesen, Elisabeth R., Kinsley, Brendan, Amiel, Stephanie A., Heller, Simon, McCance, David, Duran, Santiago, Bellaire, Shannon, Raben, Anne +1 more·2007·Diabetes Care

Abstract

OBJECTIVE—To assess the safety and efficacy of insulin aspart (IAsp) versus regular human insulin (HI) in basal-bolus therapy with NPH insulin in pregnant women with type 1 diabetes. RESEARCH DESIGN AND METHODS—Subjects (n = 322) who were pregnant or planning pregnancy were randomized to IAsp or HI as meal-time insulin in an open-label, parallel-group, multicenter study. Subjects had A1C ≤8% at confirmation of pregnancy. Insulin doses were titrated toward predefined glucose targets and A1C <6.5%. Outcomes assessed included risk of major maternal hypoglycemia, A1C, plasma glucose profiles, and maternal safety outcomes. RESULTS—Major hypoglycemia occurred at a rate of 1.4 vs. 2.1 episodes/year exposure with IAsp and HI, respectively (relative risk 0.720 [95% CI 0.36–1.46]). Risk of major/major nocturnal hypoglycemia was 52% (RR 0.48 [0.20–1.143]; P = NS) lower with IAsp compared with HI. A1C was comparable with human insulin in second (IAsp-HI −0.04 [−0.18 to 0.11]) and third (−0.08 [−0.23 to 0.06]) trimesters. A total of 80% of subjects achieved an A1C ≤6.5%. At the end of first and third trimesters, average postprandial plasma glucose increments were significantly lower with IAsp than HI (P = 0.003 and P = 0.044, respectively), as were mean plasma glucose levels 90 min after breakfast (P = 0.044 and P = 0.001, respectively). Maternal safety profiles and pregnancy outcomes were similar between treatments. CONCLUSIONS—IAsp is at least as safe and effective as HI when used in basal-bolus therapy with NPH insulin in pregnant women with type 1 diabetes and may potentially offer some benefits in terms of postprandial glucose control and preventing severe hypoglycemia.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc06-1887

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Metformin or glyburide have not shown increased adverse pregnancy outcomes.

    “oral agents such as metformin or glyburide have not shown increased adverse pregnancy outcomes and therefore can be considered.1430–1435”

    From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1430]

    The Treatments section describes insulin aspart and human insulin, not metformin or glyburide. The Pregnancy outcome section reports no significant difference between those insulin groups, but our copy does not address whether either oral agent increases adverse pregnancy outcomes (searched: metformin, glyburide, oral agents). (LLM, conf=0.78)

    Experimental — accuracy not yet measured
  • Rapid-acting insulin analogs are less likely than regular human insulin to cause hypoglycemia.

    “Rapid-acting insulin analogs are likely more able than regular human insulin to help a woman achieve postprandial blood glucose targets and are less likely to cause hypoglycemia; fetal outcomes, however, seem comparable (28–30).”
  • Fetal outcomes with rapid-acting insulin analogs seem comparable to regular human insulin.

    “Rapid-acting insulin analogs are likely more able than regular human insulin to help a woman achieve postprandial blood glucose targets and are less likely to cause hypoglycemia; fetal outcomes, however, seem comparable (28–30).”
  • Rapid-acting insulin analogs are likely more able than regular human insulin to help a woman achieve postprandial blood glucose targets.

    “Rapid-acting insulin analogs are likely more able than regular human insulin to help a woman achieve postprandial blood glucose targets and are less likely to cause hypoglycemia; fetal outcomes, however, seem comparable (28–30).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Mathiesen, E. R., Kinsley, B., Amiel, S. A., Heller, S., McCance, D., Duran, S., Bellaire, S., Raben, A., & on behalf of the Insulin Aspart Pregnancy Study Group
Affiliations
  • Rigshospitalet (DK)
  • Mater Misericordiae University Hospital (IE)
  • King's College London (GB)
  • Northern General Hospital (GB)
  • Royal Victoria Hospital (GB)
  • Unidad de Investigacion Diabetes, Hospital Virgen de Valme, Seville, Spain
  • Novo Nordisk (Denmark) (DK)
Venue
Diabetes Care
Published
2007-04-01
Volume
30
Issue
4
Pages
771-776
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2066807346
Cited by
265
References
40
Citations by year
2026: 8 · 2025: 4 · 2024: 6 · 2023: 6 · 2022: 9 · 2021: 13 · 2020: 9 · 2019: 16 · 2018: 14 · 2017: 7 · 2016: 20 · 2015: 24 · 2014: 8 · 2013: 20 · 2012: 23
FWCI
22.69
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion)
  • PubMed (publishedVersion)
  • Research Portal (King's College London) (submittedVersion)
Funders
Novo Nordisk
Topics
  • Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
Keywords
insulin aspart, regular insulin, type 1 diabetes in pregnancy, maternal hypoglycemia, multiple daily insulin injections, NPH insulin, glycemic control, HbA1c, postprandial blood glucose, nocturnal hypoglycemia, pregnancy outcomes
MeSH terms
Adult, Diabetes Mellitus, Type 1, Drug Administration Schedule, Europe, Female, Gestational Age, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Insulin, Isophane, Pregnancy, Pregnancy Complications, Pregnancy Outcome, Quality of Life, Body Mass Index, Insulin Aspart

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review